Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:03:25 EST Mon 12 Jan 2026
Enter Symbol
or Name
USA
CA



Q:SLRX - SALARIUS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SLRX - Q6.40.8101·1.011.40.84    108.00  0.5148Jan 07Jan 0715 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-07 08:45U:SLRXNews ReleaseSalarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
2025-12-19 11:12U:SLRXNews ReleaseSalarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
2025-12-18 07:50U:SLRXNews ReleaseSalarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
2025-12-01 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
2025-11-19 14:42U:SLRXNews ReleaseSalarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"
2025-11-13 08:45U:SLRXNews ReleaseSalarius Pharmaceuticals and Decoy Therapeutics Complete Merger
2025-11-12 11:01U:SLRXNews ReleaseStrong Earnings and Biotech Resilience Define the Midweek Momentum
2025-11-11 09:15U:SLRXNews ReleaseSalarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
2025-10-13 08:45U:SLRXNews ReleaseSalarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
2025-09-09 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-08-14 08:30U:SLRXNews ReleaseSalarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
2025-07-14 08:30U:SLRXNews ReleaseSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
2025-07-09 08:30U:SLRXNews ReleaseSalarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
2025-04-16 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
2025-03-26 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
2025-03-24 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
2025-02-03 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
2025-01-13 08:00U:SLRXNews ReleaseSalarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement